<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02688556</url>
  </required_header>
  <id_info>
    <org_study_id>OTX-101-2016-001</org_study_id>
    <nct_id>NCT02688556</nct_id>
  </id_info>
  <brief_title>Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca</brief_title>
  <acronym>Emerald</acronym>
  <official_title>A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharma Global FZE</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharma Global FZE</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-masked, vehicle-controlled study of the safety and efficacy of
      OTX-101 (0.09% cyclosporine nanomicellar solution) in the treatment of keratoconjunctivitis
      sicca to be conducted at approximately 50 sites.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tear Production</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Percentage of Eyes with Increase from Baseline of ≥ 10 mm in Schirmer's Test Score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Conjunctival Staining</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>change from baseline in total conjunctival staining score (lissamine green, modified National Eye Institute scale) at 12 weeks.
Conjunctival Lissamine Green Staining Grades ranged from 0 (No punctate stain in zone) to 3 (Densely concentrated micropunctate stain spots)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Corneal Staining</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>change from baseline in central corneal staining score (fluorescein, modified NEI/FDA scale) at 12 weeks.
The Expanded National Eye Institute (NEI)/Industry Workshop Scale for Corneal Staining Score was used to grade each of the 5 areas of the cornea on a 0 (No punctate stain in area) to 4 (Severe diffuse (coalescent) macropunctate stain of the area) scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Score</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>change from baseline in modified Symptom Assessment in Dry Eye (SANDE) score at 12 weeks.
A modified SANDE instrument was used to evaluate dry eye symptoms at each visit.
Subjects were asked to indicate:
frequency of dry and irritated eyes on a scale of 0 (rarely) to 100 (all the time); and
severity of dry eyes on a scale of 0 (very mild) to 100 (severe) The global symptom score is the square root of the frequency score times the severity score and will be completed at each visit. (range 0 to 100)
Negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">745</enrollment>
  <condition>Keratoconjunctivitis Sicca</condition>
  <arm_group>
    <arm_group_label>OTX-101 0.09%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.09% cyclosporine nanomicellar ophthalmic solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>vehicle of OTX-101</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <arm_group_label>OTX-101 0.09%</arm_group_label>
    <other_name>Seciera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vehicle of OTX-101</intervention_name>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of dry eye syndrome (KCS) for a period of at least 6 months

          -  Clinical diagnosis of bilateral KCS

          -  Lissamine green conjunctival staining sum score of ≥ 3 to ≤ 9 out of a total possible
             score of 12 (scoring excludes superior zones 2 and 4) in the same eye at both the
             Screening and Baseline Visits.

          -  Global symptom score (SANDE) ≥ 40 mm at both the Screening and Baseline Visits

          -  Corrected Snellen visual acuity (VA) of better than 20/200 in each eye.

        Exclusion Criteria:

          -  Use of cyclosporine ophthalmic emulsion 0.05% (Restasis®) within 3 months prior to the
             Screening Visit.

          -  Previous treatment failure (lack of efficacy) with cyclosporine ophthalmic emulsion
             0.05% (Restasis).

          -  Diagnosis of Sjögren's disease ˃ 5 years prior to the Screening Visit.

          -  Clinical diagnosis or any history of seasonal and/or perennial allergic
             conjunctivitis.

          -  Use of systemic or topical medications within 7 days prior to the Screening Visit or
             during the study period that are known to cause dry eye.

          -  Use of any topical ophthalmic medications, prescription (including anti-glaucoma
             medications) or over the counter (including artificial tears), other than the assigned
             study medication during the study period.

          -  Current active eye disease other than dry wyw syndrome (i.e., any disease for which
             topical or systemic ophthalmic medication is necessary).

          -  History of herpes keratitis.

          -  Corneal transplant

          -  Corneal refractive surgery within 6 months prior to the Screening Visit or
             postoperative refractive surgery symptoms of dryness that have not resolved.

          -  Cataract surgery within 3 months prior to the Screening Visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Martel Eye Medical Group</name>
      <address>
        <city>Rancho Cordova</city>
        <state>California</state>
        <zip>95670</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Eye Institute</name>
      <address>
        <city>Edgewood</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fifth Avenue Eye Associates</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>February 13, 2016</study_first_submitted>
  <study_first_submitted_qc>February 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2016</study_first_posted>
  <results_first_submitted>November 13, 2018</results_first_submitted>
  <results_first_submitted_qc>April 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 8, 2019</results_first_posted>
  <last_update_submitted>May 2, 2019</last_update_submitted>
  <last_update_submitted_qc>May 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>KCS</keyword>
  <keyword>dry eye</keyword>
  <keyword>cyclosporine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One subject in OTX-101 0.09% group, was never treated with study medication and is not included in any of analysis sets Additionally, because the subjects in the ITT analysis set were analyzed as randomized, one subject who erroneously received OTX-101 0.09%, was included in the Vehicle group for purposes of efficacy analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>OTX-101 0.09%</title>
          <description>0.09% cyclosporine nanomicellar ophthalmic solution</description>
        </group>
        <group group_id="P2">
          <title>Vehicle</title>
          <description>vehicle of OTX-101</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="372"/>
                <participants group_id="P2" count="373"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="347"/>
                <participants group_id="P2" count="361"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent to treat population</population>
      <group_list>
        <group group_id="B1">
          <title>OTX-101 0.09%</title>
          <description>0.09% cyclosporine nanomicellar ophthalmic solution</description>
        </group>
        <group group_id="B2">
          <title>Vehicle</title>
          <description>vehicle of OTX-101</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="371"/>
            <count group_id="B2" value="373"/>
            <count group_id="B3" value="744"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.4" spread="14.10"/>
                    <measurement group_id="B2" value="59.5" spread="14.68"/>
                    <measurement group_id="B3" value="59.0" spread="14.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="315"/>
                    <measurement group_id="B2" value="311"/>
                    <measurement group_id="B3" value="626"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="310"/>
                    <measurement group_id="B2" value="305"/>
                    <measurement group_id="B3" value="615"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tear Production</title>
        <description>Percentage of Eyes with Increase from Baseline of ≥ 10 mm in Schirmer's Test Score</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>OTX-101 0.09%</title>
            <description>0.09% cyclosporine nanomicellar ophthalmic solution</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>vehicle of OTX-101</description>
          </group>
        </group_list>
        <measure>
          <title>Tear Production</title>
          <description>Percentage of Eyes with Increase from Baseline of ≥ 10 mm in Schirmer's Test Score</description>
          <population>Intent to treat population</population>
          <units>Percentage of eyes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="371"/>
                <count group_id="O2" value="373"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6"/>
                    <measurement group_id="O2" value="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Conjunctival Staining</title>
        <description>change from baseline in total conjunctival staining score (lissamine green, modified National Eye Institute scale) at 12 weeks.
Conjunctival Lissamine Green Staining Grades ranged from 0 (No punctate stain in zone) to 3 (Densely concentrated micropunctate stain spots)</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>OTX-101 0.09%</title>
            <description>0.09% cyclosporine nanomicellar ophthalmic solution</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>vehicle of OTX-101</description>
          </group>
        </group_list>
        <measure>
          <title>Conjunctival Staining</title>
          <description>change from baseline in total conjunctival staining score (lissamine green, modified National Eye Institute scale) at 12 weeks.
Conjunctival Lissamine Green Staining Grades ranged from 0 (No punctate stain in zone) to 3 (Densely concentrated micropunctate stain spots)</description>
          <population>Intent to treat population</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="371"/>
                <count group_id="O2" value="373"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.53" spread="1.927"/>
                    <measurement group_id="O2" value="-1.16" spread="2.2064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Central Corneal Staining</title>
        <description>change from baseline in central corneal staining score (fluorescein, modified NEI/FDA scale) at 12 weeks.
The Expanded National Eye Institute (NEI)/Industry Workshop Scale for Corneal Staining Score was used to grade each of the 5 areas of the cornea on a 0 (No punctate stain in area) to 4 (Severe diffuse (coalescent) macropunctate stain of the area) scale.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>OTX-101 0.09%</title>
            <description>0.09% cyclosporine nanomicellar ophthalmic solution</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>vehicle of OTX-101</description>
          </group>
        </group_list>
        <measure>
          <title>Central Corneal Staining</title>
          <description>change from baseline in central corneal staining score (fluorescein, modified NEI/FDA scale) at 12 weeks.
The Expanded National Eye Institute (NEI)/Industry Workshop Scale for Corneal Staining Score was used to grade each of the 5 areas of the cornea on a 0 (No punctate stain in area) to 4 (Severe diffuse (coalescent) macropunctate stain of the area) scale.</description>
          <population>Intent to treat population</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="341"/>
                <count group_id="O2" value="373"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="0.533"/>
                    <measurement group_id="O2" value="-0.26" spread="0.588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptom Score</title>
        <description>change from baseline in modified Symptom Assessment in Dry Eye (SANDE) score at 12 weeks.
A modified SANDE instrument was used to evaluate dry eye symptoms at each visit.
Subjects were asked to indicate:
frequency of dry and irritated eyes on a scale of 0 (rarely) to 100 (all the time); and
severity of dry eyes on a scale of 0 (very mild) to 100 (severe) The global symptom score is the square root of the frequency score times the severity score and will be completed at each visit. (range 0 to 100)
Negative change from baseline indicates improvement.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>OTX-101 0.09%</title>
            <description>0.09% cyclosporine nanomicellar ophthalmic solution</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>vehicle of OTX-101</description>
          </group>
        </group_list>
        <measure>
          <title>Symptom Score</title>
          <description>change from baseline in modified Symptom Assessment in Dry Eye (SANDE) score at 12 weeks.
A modified SANDE instrument was used to evaluate dry eye symptoms at each visit.
Subjects were asked to indicate:
frequency of dry and irritated eyes on a scale of 0 (rarely) to 100 (all the time); and
severity of dry eyes on a scale of 0 (very mild) to 100 (severe) The global symptom score is the square root of the frequency score times the severity score and will be completed at each visit. (range 0 to 100)
Negative change from baseline indicates improvement.</description>
          <population>Intent to treat population</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="371"/>
                <count group_id="O2" value="373"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.8" spread="24.08"/>
                    <measurement group_id="O2" value="-19.1" spread="23.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>OTX-101 0.09%</title>
          <description>0.09% cyclosporine nanomicellar ophthalmic solution.
A total of 744 subjects were included in the Safety population, with 372 subjects in the OTX-101 0.09% group and 372 subjects in the Vehicle group. The only difference between the ITT and the Safety populations is that Subject 14-003 was analyzed in the Safety population according to the treatment received, which was OTX-101 0.09%</description>
        </group>
        <group group_id="E2">
          <title>Vehicle</title>
          <description>vehicle of OTX-101
A total of 744 subjects were included in the Safety population, with 372 subjects in the OTX-101 0.09% group and 372 subjects in the Vehicle group. The only difference between the ITT and the Safety populations is that Subject 14-003 was analyzed in the Safety population according to the treatment received, which was OTX-101 0.09%</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="372"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="372"/>
              </event>
              <event>
                <sub_title>Perforated ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="372"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="372"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="372"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="372"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="372"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="372"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="372"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="372"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="372"/>
              </event>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="372"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="372"/>
              </event>
              <event>
                <sub_title>Instillation site reaction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="372"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="372"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="372"/>
              </event>
              <event>
                <sub_title>Foreign body sensation in eyes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="372"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
              </event>
              <event>
                <sub_title>Posterior capsule opacification</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="372"/>
              </event>
              <event>
                <sub_title>Punctate keratitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="372"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Instillation site pain</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="372"/>
              </event>
              <event>
                <sub_title>Instillation site lacrimation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="372"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="372"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>SPARC</name_or_title>
      <organization>Sun Pharma Advanced Research Company Limited</organization>
      <phone>+912266455645</phone>
      <email>clinical.trials@sparcmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

